Human placenta-derived adherent cells induce tolerogenic immune responses

Area of Science:

• Immunology
• Cell Biology
• Regenerative Medicine

Background:

• Human placenta-derived adherent cells (PDAC) possess immunomodulatory and anti-inflammatory properties.
• PDA-001 (cenplacel-L), a PDAC cell formulation, is under investigation for autoimmune and inflammatory conditions.
• Understanding PDAC cell mechanisms is crucial for their therapeutic application.

Purpose of the Study:

• To investigate the immunoregulatory mechanisms of PDAC cells.
• To determine PDAC cell effects on T cells and dendritic cells (DC) in vitro and in vivo.
• To elucidate the role of DC modulation in PDAC cell-mediated immune tolerance.

Main Methods:

• In vivo studies using T-cell adoptive transfer and experimental autoimmune encephalomyelitis models.
• In vitro assays assessing T-cell proliferation, Th1/Th17 differentiation, and DC maturation.
• Analysis of DC phenotype (CD86 expression) and function in response to PDAC cells.
• Investigation of cyclo-oxygenase-2 (COX-2) inhibition on PDAC cell effects.

Main Results:

• PDAC cells suppressed T-cell proliferation and Th1/Th17 differentiation in vitro.
• PDAC cells reduced disease severity in experimental autoimmune encephalomyelitis and delayed type hypersensitivity models.
• PDAC cells modulated DC differentiation and maturation, inducing a tolerogenic phenotype.
• Prostaglandin E2 (PGE2) plays a role in PDAC-mediated DC modulation.

Conclusions:

• PDAC cells promote immune tolerance by modulating dendritic cell differentiation.
• These findings highlight a key mechanism for PDAC cell immunomodulation.
• PDAC cells represent a promising therapeutic strategy for immune and inflammatory diseases.